A Study of LY3314814 in Participants With Liver Impairment
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether LY3314814 can be safely prescribed in
participants with liver impairment without a dose adjustment. Participants will be on study
for 11 days with follow-up about 7 days afterward.